BioSpecifics Technologies Corp. (BSTC) Holdings Increased by Wells Fargo & Company MN

Wells Fargo & Company MN grew its stake in shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,481 shares of the biopharmaceutical company’s stock after buying an additional 4,373 shares during the quarter. Wells Fargo & Company MN owned about 0.69% of BioSpecifics Technologies worth $2,144,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BSTC. Schwab Charles Investment Management Inc. grew its stake in shares of BioSpecifics Technologies by 9.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 41,812 shares of the biopharmaceutical company’s stock worth $1,946,000 after purchasing an additional 3,541 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of BioSpecifics Technologies by 1.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 269,554 shares of the biopharmaceutical company’s stock worth $12,540,000 after purchasing an additional 3,878 shares during the last quarter. First Quadrant L P CA grew its stake in shares of BioSpecifics Technologies by 52.7% in the 4th quarter. First Quadrant L P CA now owns 11,631 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 4,015 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of BioSpecifics Technologies by 99.0% in the 4th quarter. SG Americas Securities LLC now owns 6,911 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 3,438 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its stake in shares of BioSpecifics Technologies by 5.0% in the 4th quarter. Mutual of America Capital Management LLC now owns 55,463 shares of the biopharmaceutical company’s stock worth $2,403,000 after purchasing an additional 2,652 shares during the last quarter. 56.49% of the stock is currently owned by institutional investors.

Several brokerages have recently issued reports on BSTC. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of BioSpecifics Technologies in a research note on Tuesday, March 13th. Zacks Investment Research cut shares of BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Finally, BidaskClub raised shares of BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 24th.



Shares of BSTC opened at $44.09 on Friday. The company has a market capitalization of $319.36, a PE ratio of 26.09 and a beta of 1.43. BioSpecifics Technologies Corp. has a 12-month low of $38.05 and a 12-month high of $58.79.

ILLEGAL ACTIVITY WARNING: “BioSpecifics Technologies Corp. (BSTC) Holdings Increased by Wells Fargo & Company MN” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://dakotafinancialnews.com/2018/04/14/biospecifics-technologies-corp-bstc-holdings-increased-by-wells-fargo-company-mn.html.

About BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply